Celator Pharmaceuticals – Secondary AML

Submitted By:
Published Date:
January 25, 2020

Access Program Information

This study is a Phase IV Expanded Access Protocol (EAP) of CPX-351 in patients with
secondary acute myeloid leukemia who are suitable for treatment with intensive chemotherapy.

Rare Disease:
Acute myeloid leukemia